IL17A and psoriasis: AD-MSCs have immunomodulatory potential in the treatment of psoriasis by inhibiting the production of Th17-related cytokines, such as IL-17A and TNF-α, which alleviates imiquimod (IMQ)-induced skin pathological changes associated with psoriasis in mice [108].